Abstract
A new series of mononuclear Cu(II) complexes, [Cu(L1)2]: C1, [Cu(L2)2]: C2, [Cu(L3)2]: C3 and [Cu(L4)2]: C4, with bis-O,N-bidentate Schiff base ligands (HL1: (E)-4-[(2-hydroxy-5-bromobenzylidene)amino]-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one; HL2: (E)-4-[(2-hydroxy-5-chlorobenzylidene)amino]-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one; HL3: (E)-4-[(2-hydroxy-5-hydroxybenzylidene)amino]-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one; HL4: (E)-4-[(2-hydroxy-5-nitrobenzylidene)amino]-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one) have been prepared and characterized by elemental (CHN) analyses, FT-IR and multinuclear NMR (1H and 13C) spectroscopy. Furthermore, the crystal structures of HL3, HL4 and C4 were analyzed by single-crystal X-ray diffraction (SC-XRD). The XRD studies revealed that C4 has 2:1 ligand-to-metal ratio and adapts highly distorted square planar geometry. The in vitro antibacterial activities of the synthesized ligands and their respective copper(II) complexes were elaborated by screening them against Staphylococcus aureus and Escherichia coli. The results showed a wide range of antimicrobial activity due to different electronic environments of the substituents on phenolic moiety.
Graphical Abstract
Acknowledgements
The support of this work by Ardakan University and Payame Noor University are gratefully acknowledged. H.K. thanks Prof. Mehmet Akkurt from Erciyes University for the X-ray analysis of complex C4.
Disclosure statement
No potential conflict of interest was reported by the authors.